Ultragenyx Pharmaceutical Inc. RARE

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. We have built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

We were founded in April 2010 by our President and Chief Executive Officer, Emil Kakkis, M.D., Ph.D., and are led by a management team experienced in the development and commercialization of rare disease therapeutics. Our strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Last close 15.65 2026-10-23
Market cap $1.54B 2026-06-30 share count
52-week range 12.73 - 39.89

Valuation FY2025 figures against the last close

P/S2.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-5.83

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $673.0M$560.0M$434.0M$363.3M$351.4M$271.0M$103.7M$51.5M$2.6M$133.0K
Cost of revenue ———————$1.1M$1.0K—
Gross profit ———————$50.3M$2.6M—
R&D $750.0M$698.0M$648.0M$705.8M$497.2M$412.1M$357.4M$294.0M$231.6M$183.2M
SG&A $349.0M$321.0M$310.0M$278.1M$220.0M$182.9M$161.5M$127.7M$99.9M$64.9M
Total operating expenses —————$601.1M$527.9M$422.9M$331.6M$248.1M
Operating income -$535.0M-$536.0M-$569.0M-$648.9M-$381.7M-$330.1M-$424.2M-$371.4M-$328.9M-$248.0M
Pre-tax income -$571.0M-$567.0M-$609.0M-$701.7M-$453.0M-$185.4M-$399.4M-$197.1M-$318.3M-$245.8M
Income tax $4.0M$2.0M$2.0M$5.7M$1.0M$1.2M$3.3M$514.0K$16.2M$35.0K
Net income -$575.0M-$569.0M-$607.0M-$707.4M-$454.0M-$186.6M-$402.7M-$197.6M-$302.1M-$245.9M
EPS, basic -5.83-6.29-8.25-10.12-6.70-3.07————
EPS, diluted -5.83-6.29-8.25-10.12-6.70-3.07-7.12-3.97-7.12-6.21
Shares, diluted (wtd. avg.) 98.6M90.5M73.5M69.9M67.8M60.8M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $421.0M$174.0M$214.0M$132.9M$307.6M$713.5M$433.6M$113.4M$100.5M$161.1M
Short-term investments $259.0M$436.0M$363.6M$614.8M$432.6M$488.0M$321.6M$346.3M$134.0M$219.0M
Receivables $158.0M$122.0M$73.4M$40.4M$28.4M$23.1M$32.8M$12.7M$5.2M—
Inventory $52.0M$45.0M$34.0M$26.8M$16.2M$13.0M$11.5M$7.1M$757.0K—
Total current assets $951.0M$817.0M$732.2M$883.9M$856.6M$1.30B$851.0M$522.4M$269.6M$401.7M
Property, plant and equipment $244.0M$266.0M$290.6M$259.7M$141.2M$73.5M$44.3M$20.0M$21.8M$17.1M
Goodwill $44.0M$44.0M$44.4M$44.4M$44.4M$44.4M$44.4M$44.4M$44.4M—
Other intangibles $176.0M$178.0M$166.3M$160.1M$130.8M$131.1M$129.0M$129.2M$141.5M—
Total assets $1.53B$1.50B$1.49B$1.55B$1.52B$1.76B$1.14B$719.6M$490.8M$540.6M
Accounts payable $31.0M$39.0M$42.1M$43.3M$17.1M$12.9M$12.9M$12.3M$8.9M$5.4M
Total current liabilities $384.0M$344.0M$280.4M$261.2M$181.4M$189.6M$103.3M$74.7M$71.0M$60.3M
Total liabilities $1.60B$1.24B$1.22B$1.19B$599.8M$605.2M$481.7M$110.7M$107.3M$66.7M
Retained earnings -$4.53B-$3.96B-$3.39B-$2.78B-$2.07B-$1.62B-$1.43B-$1.03B-$832.7M-$530.5M
Total equity -$80.0M$255.0M$275.0M$352.0M$922.6M$1.15B$653.8M$608.9M$383.5M$474.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$466.0M-$414.0M-$475.0M-$380.5M-$338.7M-$132.2M-$345.4M-$290.6M-$253.8M-$161.0M
Depreciation and amortisation $35.0M$36.0M$26.0M$18.2M$13.2M$12.3M$8.5M$19.5M$5.8M$3.4M
Stock-based compensation ————————$68.0M$48.3M
Capital expenditure $6.0M$7.0M$44.0M$116.1M$73.1M$43.9M$24.8M$4.1M$2.8M$10.2M
Investing cash flow $236.0M-$18.0M$168.0M-$291.7M-$195.4M-$179.1M-$13.0M-$33.3M$55.5M$91.1M
Financing cash flow $478.0M$399.0M$388.0M$501.2M$118.6M$600.3M$679.3M$336.9M$136.3M$138.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-057329.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B -500M 0 500M 1B Revenue, FY2016: 133K Net income, FY2016: -245.9M Revenue, FY2017: 2.6M Gross profit, FY2017: 2.6M Net income, FY2017: -302.1M Revenue, FY2018: 51.5M Gross profit, FY2018: 50.3M Net income, FY2018: -197.6M Revenue, FY2019: 103.7M Net income, FY2019: -402.7M Revenue, FY2020: 271M Net income, FY2020: -186.6M Revenue, FY2021: 351.4M Net income, FY2021: -454M Revenue, FY2022: 363.3M Net income, FY2022: -707.4M Revenue, FY2023: 434M Net income, FY2023: -607M Revenue, FY2024: 560M Net income, FY2024: -569M Revenue, FY2025: 673M Net income, FY2025: -575M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $133.0K $2.6M $51.5M $103.7M $271.0M $351.4M $363.3M $434.0M $560.0M $673.0M
Gross profit — $2.6M $50.3M — — — — — — —
Net income -$245.9M -$302.1M -$197.6M -$402.7M -$186.6M -$454.0M -$707.4M -$607.0M -$569.0M -$575.0M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%